Vor Biopharma CDO Departs, Transition Support Planned

Vor Biopharma ( (VOR) ) just unveiled an update.

On December 31, 2025, Vor Biopharma Inc. entered into a separation agreement with its Chief Development Officer, Dr. Qing Zuraw, following her decision to pursue other opportunities, with her employment ending the same day and severance benefits provided in line with the terms of her 2025 employment agreement and subsequent amendment. The agreement includes a general release of claims, a 12‑month non‑compete, and standard non‑disparagement and confidentiality provisions, and the company expects to engage Dr. Zuraw as a consultant to support the transition during the first quarter of 2026, signaling an effort to maintain continuity in its development operations despite the leadership change.

The most recent analyst rating on (VOR) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.

Spark’s Take on VOR Stock

According to Spark, TipRanks’ AI Analyst, VOR is a Neutral.

The score is held down primarily by weak financial performance (no revenue, large and worsening losses, and deeply negative equity). Corporate events provide a meaningful offset via Phase 3 progress and sizable financings that support continued clinical development, while technicals and valuation remain mixed and do not strongly improve the risk profile.

To see Spark’s full report on VOR stock, click here.

More about Vor Biopharma

Vor Biopharma Inc. is a biotechnology company focused on developing therapies, including through the work of senior development leadership such as its Chief Development Officer role, to advance its clinical and preclinical programs in the life sciences sector.

Average Trading Volume: 1,644,769

Technical Sentiment Signal: Strong Sell

Current Market Cap: $286.6M

See more data about VOR stock on TipRanks’ Stock Analysis page.